Terms: = Ovarian cancer AND ITK, PSCTK2, 3702, Q08881, ENSG00000113263, EMT, MGC126258, LYK, MGC126257 AND Clinical Outcome
23 results:
1. Machine learning developed a CD8
Chen R; Zheng Y; Fei C; Ye J; Fei H
Sci Rep; 2024 Mar; 14(1):5794. PubMed ID: 38461331
[TBL] [Abstract] [Full Text] [Related]
2. VSTM2L contributes to anoikis resistance and acts as a novel biomarker for metastasis and clinical outcome in ovarian cancer.
Li Y; Zhang J; Cai Y; Liu H; Yang W; Xu Y; Huang M
Biochem Biophys Res Commun; 2023 May; 658():107-115. PubMed ID: 37030064
[TBL] [Abstract] [Full Text] [Related]
3. clinical Relevance of Mortalin in ovarian cancer Patients.
Rajtak A; Czerwonka A; Pitter M; Kotarski J; Okła K
Cells; 2023 Feb; 12(5):. PubMed ID: 36899836
[No Abstract] [Full Text] [Related]
4. Expression of epithelial-mesenchymal transition biomarkers: Discoidin domain receptor 2, Snail-1, and Ovol-2 as predictors of clinical outcome in patients with epithelial ovarian carcinoma.
Harb OA; Elfeky MA; El-Beshbishi W; Obaya AA; Abdallah WM; Ibrahim A; Awd AA; Embaby A
J Cancer Res Ther; 2022; 18(4):1073-1082. PubMed ID: 36149163
[TBL] [Abstract] [Full Text] [Related]
5. A bioinformatics analysis: ZFHX4 is associated with metastasis and poor survival in ovarian cancer.
Zong S; Xu PP; Xu YH; Guo Y
J Ovarian Res; 2022 Aug; 15(1):90. PubMed ID: 35915456
[TBL] [Abstract] [Full Text] [Related]
6. Functional interaction between endothelin-1 and ZEB1/YAP signaling regulates cellular plasticity and metastasis in high-grade serous ovarian cancer.
Sestito R; Tocci P; Roman C; Di Castro V; Bagnato A
J Exp Clin Cancer Res; 2022 Apr; 41(1):157. PubMed ID: 35477522
[TBL] [Abstract] [Full Text] [Related]
7. The cyclin-dependent kinase inhibitor AT7519 augments cisplatin's efficacy in ovarian cancer via multiple oncogenic signaling pathways.
Wang L; Chen Y; Li H; Xu Q; Liu R
Fundam Clin Pharmacol; 2022 Feb; 36(1):81-88. PubMed ID: 34212421
[TBL] [Abstract] [Full Text] [Related]
8. Serotonin/HTR1E signaling blocks chronic stress-promoted progression of ovarian cancer.
Qin X; Li J; Wang S; Lv J; Luan F; Liu Y; Chen Y; Chen X; Zhao Y; Zhu J; Piao Y; Zhang W; Shi Y; Xiang R; Qu P; Wang L
Theranostics; 2021; 11(14):6950-6965. PubMed ID: 34093864
[No Abstract] [Full Text] [Related]
9. The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis ovarian cancers.
Hu Z; Cunnea P; Zhong Z; Lu H; Osagie OI; Campo L; Artibani M; Nixon K; Ploski J; Santana Gonzalez L; Alsaadi A; Wietek N; Damato S; Dhar S; Blagden SP; Yau C; Hester J; Albukhari A; Aboagye EO; Fotopoulou C; Ahmed A
Clin Cancer Res; 2021 Mar; 27(5):1570-1579. PubMed ID: 33446563
[TBL] [Abstract] [Full Text] [Related]
10. MicroRNA-150-5p promotes cell motility by inhibiting c-Myb-mediated Slug suppression and is a prognostic biomarker for recurrent ovarian cancer.
Tung CH; Kuo LW; Huang MF; Wu YY; Tsai YT; Wu JE; Hsu KF; Chen YL; Hong TM
Oncogene; 2020 Jan; 39(4):862-876. PubMed ID: 31570789
[TBL] [Abstract] [Full Text] [Related]
11. SNAI1 recruits HDAC1 to suppress SNAI2 transcription during epithelial to mesenchymal transition.
Sundararajan V; Tan M; Tan TZ; Ye J; Thiery JP; Huang RY
Sci Rep; 2019 Jun; 9(1):8295. PubMed ID: 31165775
[TBL] [Abstract] [Full Text] [Related]
12. Expression and prognostic significance of epithelial-mesenchymal transition-related markers and phenotype in serous ovarian cancer.
Song IH; Kim KR; Lim S; Kim SH; Sung CO
Pathol Res Pract; 2018 Oct; 214(10):1564-1571. PubMed ID: 30082157
[TBL] [Abstract] [Full Text] [Related]
13. TLR5/7-mediated PI3K activation triggers epithelial-mesenchymal transition of ovarian cancer cells through WAVE3-dependent mesothelin or OCT4/SOX2 expression.
Park GB; Kim D
Oncol Rep; 2017 Nov; 38(5):3167-3176. PubMed ID: 28901470
[TBL] [Abstract] [Full Text] [Related]
14. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
[TBL] [Abstract] [Full Text] [Related]
15. Involvement of AF1q/MLLT11 in the progression of ovarian cancer.
Tiberio P; Lozneanu L; Angeloni V; Cavadini E; Pinciroli P; Callari M; Carcangiu ML; Lorusso D; Raspagliesi F; Pala V; Daidone MG; Appierto V
Oncotarget; 2017 Apr; 8(14):23246-23264. PubMed ID: 28423573
[TBL] [Abstract] [Full Text] [Related]
16. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY
Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030
[TBL] [Abstract] [Full Text] [Related]
17. MMP-14 and CD44 in Epithelial-to-Mesenchymal Transition (emt) in ovarian cancer.
Vos MC; Hollemans E; Ezendam N; Feijen H; Boll D; Pijlman B; van der Putten H; Klinkhamer P; van Kuppevelt TH; van der Wurff AA; Massuger LF
J Ovarian Res; 2016 Sep; 9(1):53. PubMed ID: 27590006
[TBL] [Abstract] [Full Text] [Related]
18. Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer.
Deng J; Wang L; Chen H; Hao J; Ni J; Chang L; Duan W; Graham P; Li Y
Oncotarget; 2016 Aug; 7(34):55771-55788. PubMed ID: 27304054
[TBL] [Abstract] [Full Text] [Related]
19. The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features.
Aloia A; Petrova E; Tomiuk S; Bissels U; Déas O; Saini M; Zickgraf FM; Wagner S; Spaich S; Sütterlin M; Schneeweiss A; Reitberger M; Rüberg S; Gerstmayer B; Agorku D; Knöbel S; Terranegra A; Falleni M; Soldati L; Sprick MR; Trumpp A; Judde JG; Bosio A; Cairo S; Hardt O
Breast Cancer Res; 2015 Nov; 17(1):146. PubMed ID: 26607327
[TBL] [Abstract] [Full Text] [Related]
20. Rac1 expression in epithelial ovarian cancer: effect on cell emt and clinical outcome.
Leng R; Liao G; Wang H; Kuang J; Tang L
Med Oncol; 2015 Feb; 32(2):329. PubMed ID: 25585684
[TBL] [Abstract] [Full Text] [Related]
[Next]
